AstraZeneca India made its entry into the treatment of rare diseases in India on Tuesday. The company’s ‘Selumetinib’ for Indian patients has been approved by regulators. Regarding rare diseases, there is neither a precise estimation of the rate of mortality or morbidity in India nor an understanding of the disease burden on the public healthcare […]
Continue Reading
Because it is not anticipated that AstraZeneca’s COVID-19 antibody cocktail Evusheld will neutralize the Omicron subvariant’s XBB.1.5 subvariant, the U.S. health regulator has revoked the treatment’s emergency-use authorization. Evusheld’s use had been restricted earlier this month for the same reason by the Food and Drug Administration (FDA), and the agency’s announcement on Thursday sent U.S. […]
Continue Reading
After losing the approval for emergency use of COVID-19 vaccines, AstraZeneca has finally stopped efforts to sell its COVID-19 vaccine shots in the United States. AstraZeneca has now decided to withdraw its application for the COVID-19 vaccine Vaxzevria with the US FDA, said CEO Pascal Soriot during a press briefing. Because the US FDA has […]
Continue Reading
The US Food and Drug Administration (FDA) approved AstraZeneca’s cancer drugs Imfinzi and Imjudo in combination with chemotherapy to treat patients with stage 4 non-small cell lung cancer. This approval is based on the phase 3 data published in September 2021. Imfinzi and Imjudo with chemotherapy have shown an overall 23 percent improvement in patients […]
Continue Reading
The US Food and Drug Administration’s (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) has recommended AstraZeneca’s PT027 for the treatment of asthma in people aged 18 years and older. The Committee has voted 9 to 8 for adolescents aged 12 to 17 years, and the data do not support a favourable risk assessment for the use […]
Continue Reading
The European Commission (EC) approved Beyfortus, jointly developed by AstraZeneca and Sanofi, for the prevention of a common and highly contagious type of respiratory infection in infants. This long-acting therapy, which is also known as nirsevimab, was given marketing authorisation in the European Union (EU) for the prevention of disease from several infections caused by […]
Continue Reading
The US Food and Drug Administration (FDA) of the United States, AstraZeneca’s Evusheld is proving ineffective against Omicron COVID-19 variants. Amid new reports, the antibody combination is ineffective against the latest subvariant of Omicron COVID-19 variants, including BA.4.6. The US FDA said that it can increase the risk of COVID-19 infection for the variants that […]
Continue Reading
The US Food and Drug Administration (FDA) has approved Enhertu of AstraZeneca and Daiichi Sankyo for the treatment of adult patients with metastatic HER2-low breast cancer, who have received a prior chemotherapy in the metastatic setting during six months of completing adjuvant chemotherapy. Enhertu is a specifically designed HER2-directed antibody drug conjugate (ADC), that has […]
Continue Reading
Pascal Soriot, head of AstraZeneca has been calling on the government for the purpose of providing access to the corona virus vaccine of AstraZeneca known as Evusheld and he said that, it has been a sad situation that, the United Kingdom has been one of the few developed nations, which has not ordered the drug […]
Continue Reading
Huma Therapeutics Limited, a digital health technology company has announced partnership with AstraZeneca for the purpose of scaling the innovation of digital health. This partnership has been following the prior use cases have been executed between AstraZeneca and Huma has been reflecting a shared ambition for the purpose of improving the clinical outcomes through the […]
Continue Reading